South Florida team develops new model for antimalarial drug screening

New model for antimalarial drug screening
New model for antimalarial drug screening | Courtesy of
The University of South Florida (USF) Center for Global Health & Infectious Diseases Research recently developed a novel model for screening antimalarial drugs.

The researchers showed new chemogenic profiling that can be used to find drug targets for the deadliest strain of malaria, known as Plasmodium falciparum. This is important because the parasite has grown more and more resistant to artemisinin, the drug that is used for front-line treatment when fighting the virus. The resistance has grown even when artemisinin is used with other antimalarial drugs.

"That represents six new targets potentially as effective as artemisinin for killing the malaria parasite," Dennis Kyle, a distinguished USF health professor and co-senior author of the study, said. "There is definitely a sense of urgency for discovering new antimalarial drugs that may replace artemisinin, or work better with artemisinin, to prevent or delay drug resistance."

The researchers received funds from the National Institutes of Health to further their study.

"That interdisciplinary collaboration is where the power of this work comes to light," Kyle said. "It helps us develop the tools, the molecular techniques we need to rapidly mine huge amounts of data, and to discover new drug targets in ways not previously feasible."

Organizations in this Story

National Institutes of Health University of South Florida

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.